A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
Inclusion Criteria:
Karnofsky performance status ≥ 60 (i.e. requires occasional assistance, but is able to care for most of their personal needs)
For patients on medical treatment for Cushing's disease the following washout periods must be completed before screening assessments are performed
Exclusion Criteria:
Atlanta, Georgia 30322, United States
Ann Arbor, Michigan 48109-0944, United States
Portland, Oregon 97201, United States
Philadelphia, Pennsylvania 19104, United States
Caen Cedex9, 14033, France
Marseille Cédex 5, 13385, France
Bunkyo-ku, Tokyo 113-8603, Japan
Minato-ku, Tokyo 105-8470, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Diskapi / Ankara, Ankara 06110, Turkey (Türkiye)